MedPath

ConsultaTM CRT-D Clinical Evaluation Study

Not Applicable
Completed
Conditions
Tachyarrhythmias
Ventricular Dysfunction
Heart Failure
Interventions
Device: Bi-ventricular Implantable Cardioverter Defibrillator
Registration Number
NCT00526162
Lead Sponsor
Medtronic Bakken Research Center
Brief Summary

The purpose of the Consulta clinical study is to evaluate the overall system safety and clinical performance of the Consulta Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (CRT-D).

Detailed Description

The Consulta CRT-D is an investigational bi-ventricular device that provides atrial and ventricular tachyarrhythmia detection and therapy, cardioversion, defibrillation and cardiac resynchronization therapy.

The study will be a prospective, non-randomized, multicenter clinical study, conducted in approximately 18 centers.

To allow for sufficient experience with the device, a maximum of 80 subjects may be implanted with the Consulta device. Data will be collected at baseline (enrollment), implant, 1-, 3-, and 6- months post implant and every 6 months thereafter or until study closure (whichever occurs first), unscheduled follow-up visits, System Modifications, Technical Observations, Study Deviations, Study Exit, upon notification of new or updated Adverse Events and in case of death.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
83
Inclusion Criteria
  • Patients who have an indication for a defibrillator.
  • Patients who are optimally treated with medication.
  • Patients who are New York Heart Association (NYHA) Class III or IV
Exclusion Criteria
  • Patients with a life expectancy less than the duration of the study.
  • Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients.
  • Patients with mechanical tricuspid heart valves.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Implantation of Consulta CRT-DBi-ventricular Implantable Cardioverter DefibrillatorPatients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
Primary Outcome Measures
NameTimeMethod
Freedom From Unanticipated Serious Adverse Device Effects at 1-month Post Implant.1 month

Percentage of subjects without an unanticipated serious adverse device effects at 1-month post implant.Only subjects implanted with a Consulta device that were followed at least 28 days post-implant or have had a unanticipated device effect within 28 days after implant were included in the analysis.

Secondary Outcome Measures
NameTimeMethod
Adverse Events1 month

Number of Adverse Events reported in the implanted subjects.

System Performance Assessed by Holter Records1 month follow-up

The first 20 digital Holter records that were successfully collected in the total of 80 implanted subjects were analysed on observation of device features, ventricular arrhythmia detection times and device classification of ventricular arrhythmias.

System Performance Assessed by Save to Disk Files1 month follow-up

94 Save to Disk files were reviewed on observation of device features, ventricular arrhythmia detection times and device classification of ventricular arrhythmias.

System Performance Assessed by Technical Observations1 month follow-up

Reported technical observations will be reviewed to determine if there are any device performance issues.

Trial Locations

Locations (1)

Hospital

🇩🇪

Bonn, Germany

© Copyright 2025. All Rights Reserved by MedPath